Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2016

NxSTAGE MEDICAL, INC.

(Exact name of registrant as specified in its charter)



Delaware	000-51567	04-3454702
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

350 Merrimack Street, Lawrence, MA		01843
(Address of principal executive offices)		(Zip Code)

(978) 687-4700

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

NxStage Medical, Inc. (“NxStage”) and DaVita Healthcare Partners Inc. (“DaVita”) are parties to a Second Amended and Restated National Service Provider Agreement dated as of March 1, 2013 (“DaVita Agreement”) pursuant to which DaVita purchases the NxStage ^® System One ^TM and related supplies for home hemodialysis therapy in the United States. Effective as of June 13, 2016, NxStage and DaVita have amended the DaVita Agreement to extend its term through December 31, 2018, with monthly renewals thereafter unless terminated by either party with 30 days’ prior notice.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NxStage Medical, Inc.

By: Matthew W. Towse

Matthew W. Towse

Chief Financial Officer

Date: June 13, 2016